SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 33.6% in November

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 260,200 shares, a decrease of 33.6% from the October 31st total of 391,800 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 0.3 days.

SciSparc Stock Performance

NASDAQ:SPRC traded down $0.01 during mid-day trading on Friday, hitting $0.21. 156,131 shares of the company’s stock traded hands, compared to its average volume of 1,551,149. SciSparc has a 1 year low of $0.21 and a 1 year high of $9.80. The firm’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.51.

Institutional Investors Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new position in shares of SciSparc Ltd. (NASDAQ:SPRC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned about 5.59% of SciSparc at the end of the most recent reporting period. 25.06% of the stock is owned by institutional investors.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.